Additional Information
Market:ASX
Sector:Pharma & Biotech
EPIC:PXS
Latest Price: 0.99  (0.00%)
52-week High:2.91
52-week Low:0.61
Market Cap:226.83M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Pharmaxis

Pharmaxis (ASX: PXS) is a specialty pharmaceutical company focused on the development of new products for the diagnosis and treatment of chronic respiratory and immune disorders.

Pharmaxis Ltd buoyed by asthma study results

Thursday, March 11, 2010
Pharmaxis Ltd buoyed by asthma study results

Australian pharmaceutical company Pharmaxis (ASX: PXS) today announced the successful completion of a Phase IIa dose profiling study with its new anti‐inflammatory agent ASM8 in patients with allergic asthma.

Pharmaxis’ chief executive offficer, Dr Alan Robertson said the clinical data demonstrated the potential value of this approach for treating asthma.

The moderate to severe sector of the asthma market, which is the target of ASM8, represents a significant commercial opportunity for Pharmaxis, and is under-served by current therapies.

The Pharmaxis study met the pre‐defined primary efficacy and safety endpoints and ASM8 was found to be safe at all doses tested and particularly effective at an inhaled dose of 8mg once per day.

ASM8 is the leading clinical‐stage asset in the portfolio of drug candidates acquired by Pharmaxis in its recent takeover of the Canadian company, Topigen Pharmaceuticals Inc.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.